
Kopran Q2 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- Kopran expects to double its API business revenues in the next three years due to capacity expansions and higher-value new molecules.
- Formulation business is projected to grow steadily, with improved margins and diversification into regulated markets like the US, UK, Europe, Latin America, and Southeast Asia.
- New product filings and approvals (e.g., Amoxiclav, Dapagliflozin, Ticagrelor, Rivaroxaban) are expected to drive growth from 2024 onward, with significant regulated market traction from 2025.
- Growth rate projections: 10%-15% in the next 1-2 years, increasing to 20%-25% later.
- Integration from API to formulation (vertical integration) is expected to strengthen over 3-4 years, reducing volatility and enhancing margins.
- Geographic diversification will gradually reduce dependence on South Africa/Africa, with faster expansion in other regions.
- Panoli facility’s environmental clearance and commercial launch expected in the coming year will contribute additional capacity and sales.
See what Kopran management said on margin guidance — free account, 30 seconds.
Fundraise plans
- The company currently has a low debt-equity ratio of around 2%, primarily due to working capital needs.
- There are no expectations or plans to take on any further loans in the near future.
- Working capital is currently locked in GST, expected to be released in the next 3-4 months, which will fund growth.
- The management does not indicate any plans for fundraising through equity in the near term.
- Growth is expected to be funded through internal accruals and released working capital rather than new borrowing or equity issuance.
See what Kopran management said on order book — free account, 30 seconds.
Capex plans
Yes- Kopran Limited is awaiting environmental clearance for two multiproduct plants at the Panoli facility, which represents a major spare capacity expected to contribute to revenue by next year.
- The company has completed planned expansions related to the Production Linked Incentive (PLI) scheme despite not receiving PLI approval, implying continued investment in capacity without incentives.
- New capacities and expansions in API business along with newer, higher-value molecules are key growth drivers.
- Kopran is focused on developing new products such as Amoxiclav formulations, diabetes-related APIs (Dapagliflozin, Empagliflozin), and cardiac products (Ticagrelor, Rivaroxaban, Apixaban) which have bioequivalence studies underway and dossiers to be filed by end of 2024.
- No immediate plans for inorganic growth or acquisitions, but may consider long-term opportunities if they arise.
Track Kopran — get its next earnings analysis in your feed
How does Kopran rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Kopran rank in Pharmaceuticals & Biotechnology?
Compare Kopran against every Pharmaceuticals & Biotechnology company (Q2 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Kopran's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem